Was #8166 the results from an AI question submission Phil? Just asking. |
Would someone like to comment on a CEO of a medium LSE company such as OXB takes on the role of chairman of another company. Please give examples. If there are many I will defer to the greater knowledge of this board but surely as CEO you need to put all your energy into OXB? I'm also still looking for the green shoots of a major announcement. Hoping daily to have missed the signs. Come on OXB, the future is brighter than ever. |
Especially since it jumped 3% at open. Dropped 6% in one move down at 13:00.
I can only think that it is someone like Blackrock, buying at £2+ and taking a 50% profit. |
And once again we head south for no apparent reason. A 3% drop seems a lot given we think things are going well ...... |
We're in a year which at worst is going to be "roughly" breakeven.
We've just added 20m Euros to the cash pile.
We're waiting to hear who the new commercial multiple myeloma manufacturing partner is.
Then there is the news about stuff which we don't know yet.
And... the price drops.
Sometimes you just have to accept that it's a nice day outside and take that as the little victory. |
Thanks CousinIT |
There's a bit of stock about.You can buy 15,000 at three quid on quote and deal. |
I shouldn't have posted that. The market maker hadn't realised he had accidently leaned on the 'up' button until then.... |
So, no new data and the price goes, up! |
Much appreciated Cousin, thanks very much for the report. |
 If the other chap that was there doesn't report back, I can.
Steadfastly nothing financial nor commercial was said that hasn't been announced already.
Appreciate that there may be confirmation bias here, but the laser focus on delivering the 3 year targets was evident and the understated confidence of doing this also.
Impression given that cost savings are complete and employee morale is good with appreciation of wider market (biotech winter) and that OXB can grow significantly from here with the current strategy. This includes the newer sites and the cross transferring of wider capabilities to each. Any recruitment is also attracting high calibre candidates.
Given the 'on script' performance in anything remotely market sensitive, questions around the long term did provoke responses about being THE best, go to provider in the CGT CDMO space. Technology agnostic but aiming to keep advancing through internal R&D and, by implication, M&A were an exceptional opportunity to present itself. That was about the most passionate Frank became, although there were a few nice touches of humour during the meeting. |
ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board
Tue, Jun 25, 2024 08:26 CET Report this content
Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies (OSE:AZT) is pleased to announce the nomination of Dr. Frank Mathias as the new Chairman of the Board.
Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global pharmaceutical companies, including Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he was awarded the “EY Entrepreneur of the Year” title in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University.
“We are very pleased to nominate Frank Mathias as our new Chairman of the Board,” said Jon R. Sandberg, Chairman of the Nomination Committee. “Frank Mathias’ extensive experience and visionary leadership make him the ideal candidate to guide our company into its next phase of development, commercialization and growth.”
“I am honoured to join ArcticZymes at such a pivotal time,” said Dr. Frank Mathias. “The innovative enzyme solutions developed by ArcticZymes have made significant contributions to advancements in biomanufacturing, enhancing efficiency and quality across the industry. I look forward to contributing to the company’s continued success and collaborative growth.”
About us
ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world. We provide our customers with cold-adapted enzymes from the arctic environment with unique features including heat lability and activity in challenging environments, as well as, customised engineered novel features which can be easily integrated to fuel their innovations. |
It might be urban myth, but I'm sure I remember a court case many years ago where the manager had signed up a new but promising pop group with a 50/50 contract where he would take care of everything.
They went on to do really quite well and he did take care of everything, but the small print was that he got 50% of gross, whilst they were on 50% of what was left and after one European tour it was 50% of nothing.
I'd bet another pound of Dom's money that Mike Tyson's deal with Don King was written in the same ink.
The contributors here who have been to previous AGMs said that young Mr Grace turns up every year. Hope he's still going after the madness of the covid years. |
H, don’t forget our 20yr longstanding lottery 50/50 agreement. I’m sure any great secrets would’ve been shared by now. |
Disappointing GH, but tempered by the fact that I'm winning £180m on the Euromillions tonight ;)
I doubt any great secrets were revealed. |
Last minute event meant I couldn’t attend today. Feedback from any one who made it? |
"just looking for patterns Phil (out of boredom really) "That reminds me of a tale relating to WC Fields.He's sitting in his dressing room,when a friend enters the room,to find the comedian reading the bible."Hey Bill,i didn't know you were a religious man?"........."I'm not",replied Fields,"i'm looking for loopholes,just looking for loopholes". |
I'm just looking for patterns Phil (out of boredom really) but it seems reasonable to me that if they gave us some pretty good updates as the year turned, that they will do similar again at the half year - then of course the actual half year results in detail at the interims in September.
But they might not.
You've seen my posts for years, so you know my glass is half full, but I'm pretty convinced (in fact just convinced) that the story which got ever better in the first few releases of this year is far from finished.
You know my reasons (listed here many times) but I'm hoping that Frank or whoever presented today was very "reassuring" for those who attended. Hopefully we will find out soon... |
As you say Harry, it makes more sense to give metrics for H1, so either this Friday or sometime next week. |
Nothing tagged on to the vote results |
If there is a business update Dom, then I would have expected it either first thing this morning or tagged on to the RNS with the result of the AGM votes later.
As for what they say informally this afternoon, well hopefully we will get to hear what that was by first-hand account a bit later.
I think we all realise that of the things which we actually "know" then the multiple myeloma news from 20th March is probably the biggest.
A little bit more about that would be very welcome. |
3:00pm start. Doesn't suggest they are making time for a business update? |
The Company intends to hold its AGM on Monday 24 June 2024 at the offices of Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m. |
Is the agm today? |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
